Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xin Yao
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0002-1544-7273
Observed ORCID:
0000-0002-1544-7273
OpenAlex ID:
A5137105153
Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.
2026
·
Xinan Sheng
, Shusuan Jiang
, et al.
·
Journal of Clinical Oncology
·
2
Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study
2026
·
Jie Lou
, Yi Ren
, et al.
·
Annals of Medicine
PDF
Multimodal deep learning model for AI-based functional prognostic risk stratification in patients undergoing radical nephrectomy
2026
·
Yunhan Luo
, Yatian Wang
, et al.
·
Nature Communications
Efficacy of fruquintinib (F) plus sintilimab (S) versus axitinib (A) or everolimus (E) by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma (RCC): A subgroup analysis of the FRUSICA-2 study.
2026
·
Kaiwei Yang
, Dingwei Ye
, et al.
·
Journal of Clinical Oncology
Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden.
2026
·
Yuan-Yuan Qu
, Zhisong He
, et al.
·
Journal of Clinical Oncology
A phase 1b study of SYS6002 in advanced solid tumors.
2026
·
Yao Zhu
, Dingwei Ye
, et al.
·
Journal of Clinical Oncology
Minimally Invasive Partial versus Radical Nephrectomy for Non-metastatic pT3a Renal Cell Carcinoma: a Multicenter Matched Cohort Study
2026
·
Xiangpeng Zou
, Zhenhua Liu
, et al.
·
International braz j urol
Show more works
View as search
Works count:
7
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type